Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

Current Treatment Landscape and Emerging Therapies for Metastatic Triple-Negative Breast Cancer

Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression

Frontiers Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer

Cancers, Free Full-Text

Full article: New insights into the discovery of drugs for triple-negative breast cancer metastasis

Patient-derived xenograft models in cancer therapy: technologies

Frontiers Decoding TROP2 in breast cancer: significance, clinical implications, and therapeutic advancements

Frontiers The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer

Cancers, Free Full-Text

Frontiers Immune Checkpoint Inhibitors in Triple Negative Breast

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming

The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer, Experimental Hematology & Oncology

Frontiers Current Triple-Negative Breast Cancer Subtypes